Insider Selling: Penumbra, Inc. (NYSE:PEN) EVP Sells $161,466.00 in Stock

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the business’s stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $269.11, for a total transaction of $161,466.00. Following the completion of the sale, the executive vice president now directly owns 66,353 shares of the company’s stock, valued at approximately $17,856,255.83. The trade was a 0.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Johanna Roberts also recently made the following trade(s):

• On Monday, March 3rd, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $287.43, for a total transaction of $172,458.00.

Penumbra Stock Down 4.0 %

Shares of NYSE PEN opened at $262.37 on Friday. The company has a market capitalization of $10.11 billion, a P/E ratio of 771.66, a P/E/G ratio of 2.83 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. The company has a 50 day simple moving average of $274.48 and a 200-day simple moving average of $245.61. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $310.00.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company had revenue of $315.52 million during the quarter, compared to analyst estimates of $311.63 million. On average, equities research analysts predict that Penumbra, Inc. will post 3.67 earnings per share for the current year.

Institutional Trading of Penumbra

A number of hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new position in Penumbra during the fourth quarter worth about $573,000. State Street Corp boosted its position in shares of Penumbra by 0.3% during the 3rd quarter. State Street Corp now owns 1,236,671 shares of the company’s stock worth $240,298,000 after purchasing an additional 3,863 shares during the period. E. Ohman J or Asset Management AB increased its holdings in Penumbra by 10.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company’s stock valued at $5,061,000 after purchasing an additional 2,000 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Penumbra by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company’s stock valued at $64,493,000 after purchasing an additional 3,807 shares during the period. Finally, Geode Capital Management LLC raised its position in Penumbra by 1.7% in the third quarter. Geode Capital Management LLC now owns 655,572 shares of the company’s stock valued at $127,417,000 after purchasing an additional 11,257 shares during the period. 88.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. UBS Group upped their price target on shares of Penumbra from $305.00 to $320.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Royal Bank of Canada increased their target price on Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a report on Wednesday, February 19th. Canaccord Genuity Group lifted their price target on Penumbra from $323.00 to $340.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Needham & Company LLC reissued a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. Finally, Bank of America began coverage on Penumbra in a report on Friday, March 14th. They issued a “buy” rating and a $320.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $294.47.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.